MedTrace Logo

The Effect of SGLT2 Inhibitors on Heart Rate Variability and BDNF Levels in Patients With Type 2 Diabetes

NCT05164523 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 64

Last updated 2023-09-05

No results posted yet for this study

Summary

Cardiac autonomic neuropathy (CAN) in diabetic patients is an indicator of autonomic nervous system dysfunction and is an important marker for cardiovascular events. Very promising results have been obtained with SGLT2 inhibitors in both cardiac and renal outcomes. The aim is to examine the effects of SGLT2 inhibitor use on cardiac autonomic neuropathy, heart rate variability, sympathetic and parasympathetic nervous system parameters, and their relationship with BDNF levels, one of the neuroinflammatory markers.

Conditions

Interventions

DIAGNOSTIC_TEST

24-hour rhythm Holter

Before starting their newly prescribed medication, the investigators will apply 24-hour rhythm Holter and repeat it at the end of the trial.

DIAGNOSTIC_TEST

36 item Short Form Survey (SF-36)

Before starting their newly prescribed medication, the investigators will apply SF-36 survey and repeat it at the end of the trial.

Sponsors & Collaborators

  • Goztepe Training and Research Hospital

    lead OTHER

Principal Investigators

  • Ayse N Erbakan, MD · Istanbul Medeniyet University Goztepe Research and TRaining Hospital

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2022-12-21
Completion
2022-12-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05164523 on ClinicalTrials.gov